Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Medication-induced systemic lupus erythematosus.

T L Skaer1

  • 1College of Pharmacy, Washington State University, Pullman.

Clinical Therapeutics
|July 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antidepressant prescribing patterns: a comparison of blacks and whites in a medicaid population.

Clinical drug investigation·2008
Same author

The effects of soy milk and isoflavone supplements on cognitive performance in healthy, postmenopausal women.

The journal of nutrition, health & aging·2007
Same author

Trends in the rate of depressive illness and use of antidepressant pharmacotherapy by ethnicity/race: an assessment of office-based visits in the United States, 1992-1997.

Clinical therapeutics·2001
Same author

The need for an iterative process for assessing economic outcomes associated with SSRIs.

PharmacoEconomics·2001
Same author

Use of lamotrigine in a patient with bipolar disorder and psychiatric comorbidity.

Clinical therapeutics·2000
Same author

Sulfonylurea pharmacotherapy regimen adherence in a Medicaid population: influence of age, gender, and race.

The Diabetes educator·1999

Systemic lupus erythematosus (SLE) is a complex autoimmune condition. Medication-induced SLE (MI-SLE) presents differently than idiopathic SLE, with distinct symptoms and patient demographics.

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Background:

  • Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease with unclear etiology, involving genetic, hormonal, and environmental factors.
  • Idiopathic SLE predominantly affects young women (10:1 ratio) and is unpredictable, with varied symptoms and potential organ involvement.
  • Medication-induced SLE (MI-SLE) differs epidemiologically, often presenting with musculoskeletal symptoms and rare renal/CNS involvement, with no female predominance.

Purpose of the Study:

  • To differentiate the characteristics of medication-induced SLE (MI-SLE) from idiopathic SLE.
  • To identify key risk factors and clinical presentations associated with drug-induced lupus.
  • To highlight the importance of careful patient monitoring and therapeutic selection in managing SLE.

Main Methods:

Related Experiment Videos

  • Comparative analysis of epidemiological and clinical features between idiopathic SLE and MI-SLE.
  • Review of medications known to induce or exacerbate SLE symptoms.
  • Examination of diagnostic criteria and patient demographics for different SLE types.

Main Results:

  • MI-SLE predominantly affects Caucasian patients with no gender bias and is associated with musculoskeletal symptoms, unlike idiopathic SLE's broader organ involvement.
  • Hydralazine and procainamide are common culprits for drug-induced SLE, typically in patients over 50.
  • Estrogen-containing contraceptives and ibuprofen can worsen idiopathic SLE symptoms.

Conclusions:

  • Medication-induced SLE has distinct epidemiological and clinical profiles compared to idiopathic SLE.
  • Accurate diagnosis requires differentiating between idiopathic and drug-induced forms of lupus.
  • Judicious patient monitoring and informed therapeutic choices are crucial for effective SLE management.